Top News

Regulus Gets $80.9M In Financing Efforts




La Jolla-based biopharmaceuticals firm Regulus Therapeutics, which is developing microRNA-based biopharmaceuticals aimed at oncology, fibrosis, hepatitis C and metabolic diseases, said it has raised $80.9M in total proceeds from its IPO, a private placement, and convertible note. The firm said $50.9M came from its sale of common stock, $25.0M in a private placement to AstraZeneca AB, and $5.0M from a convertible note sale to Biogen Idec. The firm said those funds will enable it to "executive its current strategic objectives" for the foreseeable future.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel